These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 18577160)
1. Beyond insulin replacement: addressing the additional needs of the diabetes patient. Dailey G Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():83-97. PubMed ID: 18577160 [TBL] [Abstract][Full Text] [Related]
2. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Bonora E Int J Clin Pract Suppl; 2007 Aug; (154):19-28. PubMed ID: 17593274 [TBL] [Abstract][Full Text] [Related]
3. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Mathieu C; Bollaerts K Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275 [TBL] [Abstract][Full Text] [Related]
4. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Niswender K Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648 [TBL] [Abstract][Full Text] [Related]
5. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors. Kumar A Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862 [TBL] [Abstract][Full Text] [Related]
6. What to add in with metformin in type 2 diabetes? Petrie JR; Adler A; Vella S QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663 [TBL] [Abstract][Full Text] [Related]
9. Advances in the treatment of type 2 diabetes mellitus. Israili ZH Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322 [TBL] [Abstract][Full Text] [Related]
10. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Blonde L Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303 [TBL] [Abstract][Full Text] [Related]
11. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? Halimi S Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. Penfornis A; Borot S; Raccah D Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590 [TBL] [Abstract][Full Text] [Related]
13. Incretin-based therapies in type 2 diabetes: a review of clinical results. Bosi E; Lucotti P; Setola E; Monti L; Piatti PM Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515 [TBL] [Abstract][Full Text] [Related]
14. Clinical decisions. Management of type 2 diabetes. Goldberg RB; Holman R; Drucker DJ N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869 [No Abstract] [Full Text] [Related]
15. Beyond glycemic control: treating the entire type 2 diabetes disorder. Brunton S Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276 [TBL] [Abstract][Full Text] [Related]
17. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Peters AL Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S20-7. PubMed ID: 19952300 [TBL] [Abstract][Full Text] [Related]
18. Which oral agent to use when metformin is no longer effective? Bannon M QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402 [No Abstract] [Full Text] [Related]
19. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455 [TBL] [Abstract][Full Text] [Related]
20. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Chaudhuri A; Dandona P Diabetes Obes Metab; 2011 Oct; 13(10):869-79. PubMed ID: 21569185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]